Skip to main
IRON

IRON Stock Forecast & Price Target

IRON Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Disc Medicine Inc. has seen an increase in its probability of success for bitopertin's FDA approval to 100%, reflecting strong confidence in its clinical trials demonstrating significant efficacy. The company also holds promising potential for its other candidate, DISC-0974, with analysts suggesting a favorable risk/reward profile stemming from expected Phase 2 data in myelofibrosis-related anemia. These positive developments, combined with a revised price target of $114 based on comprehensive assessments and an expedited timeline for the bitopertin launch, position Disc Medicine as a compelling investment opportunity in the biopharmaceutical sector.

Bears say

Disc Medicine Inc faces a negative outlook primarily due to concerns surrounding the efficacy and safety of its lead asset, bitopertin, which may not yield statistically significant treatment benefits in its Phase 3 trial, leading to potential setbacks in regulatory approval. Furthermore, there are indications that the commercial opportunities for bitopertin in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) could be more limited than previously anticipated, with no strong analogs for comparison. Additionally, the company operates with constrained cash reserves, raising the risk of needing additional funding to support its development pipeline, which could further impact its financial stability and market position.

IRON has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Disc Medicine Inc (IRON) Forecast

Analysts have given IRON a Buy based on their latest research and market trends.

According to 9 analysts, IRON has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Disc Medicine Inc (IRON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.